DOCSLIB.ORG

Ondansetron and the Risk of Cardiac Arrhythmias: a Systematic Review and Postmarketing Analysis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ondansetron and the Risk of Cardiac Arrhythmias: a Systematic Review and Postmarketing Analysis TOXICOLOGY/ORIGINAL RESEARCH Ondansetron and the Risk of Cardiac Arrhythmias: A Systematic Review and Postmarketing Analysis Stephen B. Freedman, MDCM, MSc; Elizabeth Uleryk, BA, MLS; Maggie Rumantir, MD; Yaron Finkelstein, MD* *Corresponding Author. E-mail: yaron.fi[email protected]. Study objective: To explore the risk of cardiac arrhythmias associated with ondansetron administration in the context of recent recommendations for identification of high-risk individuals. Methods: We conducted a postmarketing analysis and systematically reviewed the published literature, grey literature, manufacturer’s database, Food and Drug Administration Adverse Events Reporting System, and the World Health Organization Individual Safety Case Reports Database (VigiBase). Eligible cases described a documented (or perceived) arrhythmia within 24 hours of ondansetron administration. The primary outcome was arrhythmia occurrence temporally associated with the administration of a single, oral ondansetron dose. Secondary objectives included identifying all cases associating ondansetron administration (any dose, frequency, or route) to an arrhythmia. Results: Primary: No reports describing an arrhythmia associated with single oral ondansetron dose administration were identified. Secondary: Sixty unique reports were identified. Route of administration was predominantly intravenous (80%). A significant medical history (67%) or concomitant use of a QT-prolonging medication (67%) was identified in 83% of reports. Approximately one third occurred in patients receiving chemotherapeutic agents, many of which are known to prolong the QT interval. An additional third involved administration to prevent postoperative vomiting. Conclusion: Current evidence does not support routine ECG and electrolyte screening before single oral ondansetron dose administration to individuals without known risk factors. Screening should be targeted to high-risk patients and those receiving ondansetron intravenously. [Ann Emerg Med. 2014;64:19-25.] Please see page 20 for the Editor’s Capsule Summary of this article. A feedback survey is available with each research article published on the Web at www.annemergmed.com. A podcast for this article is available at www.annemergmed.com. 0196-0644/$-see front matter Copyright © 2013 by the American College of Emergency Physicians. http://dx.doi.org/10.1016/j.annemergmed.2013.10.026 INTRODUCTION (“electrolyte abnormalities, congestive heart failure, Background bradyarrhythmias, or patients taking other medicinal products ” 4 Ondansetron hydrochloride is a potent antiemetic that that lead to QT prolongation ). 1 antagonizes serotonin at 5-hydroxytryptamine3 receptors. Between 1995 and 2009, administration in US emergency Importance departments (EDs) increased more than 330-fold, from 38,000 The identification of high-risk individuals is important because to 12.6 million doses.2 Pediatric usage has also increased, with drugs are frequently administered in the ED without complete more than 2 million doses administered to children in US EDs knowledge of a patient’s medication or medical history, and the each year, greater than 85% by the oral route.3 In September opportunity for monitoring of adverse drug events may be limited.8,9 2011, the Food and Drug Administration (FDA) issued a Consequently, to identify at-risk individuals, diagnostic investigations communication warning that ondansetron may induce fatal that might not otherwise be indicated are often required. For example, arrhythmias.4 In June 2012, the FDA issued an update linking individuals with vomiting may have electrolyte abnormalities; the risk of QT prolongation to the administration of a 32-mg however, in practice, significant abnormalities are uncommon and intravenous dose. Despite this, screening recommendations testing is not routinely recommended.10 Similarly, long-QT remain unchanged5-7 and continue to recommend that syndrome, a rare and asymptomatic disorder,11 typically remains ondansetron be avoided in patients with congenital long-QT undiagnosed until a complication occurs. Approximately 16,000 syndrome and that ECG monitoring and serum electrolyte screening ECGs need to be performed to identify a single screening be performed in all potentially susceptible patients asymptomatic long-QT syndrome case.12 Volume 64, no. 1 : July 2014 Annals of Emergency Medicine 19 Ondansetron and Risk of Cardiac Arrhythmias Freedman et al Editor’s Capsule Summary administration of a single oral ondansetron dose. Our secondary objectives were to identify all pediatric (<18 years) and adult What is already known on this topic (18 years) cases associating ondansetron administration (any Recently, the Food and Drug Administration issued a dose, frequency, or route) to the development of an arrhythmia warning that ondansetron may induce fatal and to evaluate causality. arrhythmias, leading to concerns about emergency department use. Study Selection Eligible cases described a documented arrhythmia or event What question this study addressed perceived as an arrhythmia and ondansetron administration up to This systematic review analyzed available sources to 24 hours preceding the event. We selected this timeframe to identify cases of arrhythmia temporally associated ensure comprehensiveness and the inclusion of all potentially with the administration of a single oral ondansetron relevant cases catalogued by global pharmacovigilance dose. A secondary outcome was identifying all cases registries, including those associated with long-term use. Two associating ondansetron administration to an investigators with expertise in outcomes-based research (S.B.F.) arrhythmia. and clinical pharmacology (Y.F.) independently screened all abstracts to assess eligibility. Excluded cases were filed with a What this study adds to our knowledge reason. Disagreements were resolved through discussion until No reports describing an arrhythmia associated with achievement of consensus. Articles deemed appropriate single oral ondansetron dose administration were underwent detailed, full-text review. Adverse drug reaction identified. registry reports were reviewed manually. How this is relevant to clinical practice Data Extraction This study supports the safety of the clinical practice Cases underwent independent data abstraction by 2 authors of administering a single oral ondansetron dose to (S.B.F., M.R.) using a standardized form. Disagreements were low-risk patients without the need for screening resolved through discussion until achievement of consensus. evaluations. Information extracted included age, indication, dose, route, concomitant medications, event description and timing, and causal association. The presence of a significant medical history was assessed by the 2 reviewers and required a consensus opinion based on the assumptions that would be expected by a physician Goals of This Investigation providing clinical care and was focused on the presence of Current regulatory agency communications have resulted in preexisting cardiac disease (eg, heart failure, personal or family significant uncertainty and confusion among clinicians who 13 history suggestive of long-QT syndrome, other arrhythmias) or use ondansetron frequently. Although the ability of high-dose disorders associated with electrolyte abnormalities (eg, short-gut intravenous ondansetron to prolong the QT interval is not in syndrome, diuretic use, renal disease). dispute, the need for universal screening is. We sought to identify all reports describing an association between ondansetron administration and arrhythmia occurrence, with a focus on single Data Sources oral dose administration, a common practice in EDs. Published Literature. The search strategy was developed through consultation with a professional research librarian (E.U.) with experience in conducting systematic reviews.17 The strategy MATERIALS AND METHODS contained a broad series of subject headings and keywords Search Strategy relating to ondansetron, arrhythmias, and cardiovascular disease. We conducted a systematic review of the published literature, in We ran the initial searches (Appendix E1, Table E1, available accordance with Preferred Reporting Items for Systemic Reviews online at http://www.annemergmed.com) in October 2011 14,15 and Meta-Analyses guidelines. Additionally, we explored the (most recent update, December 19, 2012), using the OvidSP, grey literature (which includes reports, theses, conference Thomson Reuters, and SciVerse search platforms in the following proceedings, translations, bibliographies, and other documents databases: MEDLINE, EMBASE, Web of Knowledge/Science “ that are not available through the conventional, commercial (Conference Proceedings Citation Index), and Scopus. Databases ” 16 distribution channels ) and global adverse drug reaction and were searched from creation to December 2012, with no pharmacovigilance registries to identify all relevant reports. language restrictions. The reference lists of all included articles and relevant reviews were hand-searched. Objectives Grey Literature. The New York Academy of Medicine Grey The primary objective of this study was to identify all reported Literature Report, FDA Web site (http://www.fda.gov/drugs/ arrhythmias occurring in temporal association with the drugsafety/default.htm), OpenGrey (System for Information on 20 Annals of Emergency Medicine Volume 64, no. 1 : July 2014 Freedman et al Ondansetron and Risk of Cardiac Arrhythmias Grey Literature in Europe; http://www.opengrey.eu/), the 1120 Articles
Load more

Recommended publications
  • Selegiline Orally Disintegrating Tablet in the Treatment of Parkinson's Disease
    DRUG PROFILE Selegiline orally disintegrating tablet in the treatment of Parkinson’s disease Anthony Clarke & Mono- and adjunctive therapy with the oral monoamine oxidase B inhibitor selegiline has Joseph Jankovic† been used to treat motor complications resulting from long-term treatment of Parkinson’s †Author for correspondence disease. However, oral selegiline undergoes extensive first-pass metabolism resulting in low Parkinson’s Disease Center and Movement Disorders bioavailability and production of amphetamine and other metabolites, as well as Clinic, Baylor College of compromised efficacy and tolerability. An orally disintegrating tablet of selegiline utilizing Medicine, Department of Zydis® technology undergoes markedly reduced presystemic metabolism, thus providing Neurology, The Smith Tower, Suite 1801 higher plasma concentrations and lower levels of amphetamine metabolites. As an adjunct 6550 Fannin, Houston, to levodopa, selegiline orally disintegrating tablet has been found to significantly reduce TX 77030, USA ‘off’ time, increase ‘on’ time, and improve motor function in Parkinson’s disease patients Tel.: +1 713 798 5998 Fax: +1 713 798 6808 experiencing ‘wearing off’ episodes. This article provides an overview of the Zydis [email protected] technology, the rationale for its application in delivering selegiline, and results from clinical trials of selegiline orally disintegrating tablet in patients with Parkinson’s disease. Although conventional oral administration is study was carried out in part to evaluate poten- the preferred and more convenient route of tially neuroprotective effects of selegiline in drug delivery, it has some disadvantages. Phar- patients with early PD. While results demon- macokinetic limitations to conventional oral strated that selegiline conferred some clinical administration can include poor absorption and benefit, they did not permit any conclusions enzymatic degradation of the drug within the regarding the medication’s neuroprotective effects gastrointestinal tract.
    [Show full text]
  • Medications and Alcohol Craving
    Medications and Alcohol Craving Robert M. Swift, M.D., Ph.D. The use of medications as an adjunct to alcoholism treatment is based on the premise that craving and other manifestations of alcoholism are mediated by neurobiological mechanisms. Three of the four medications approved in the United States or Europe for treating alcoholism are reported to reduce craving; these include naltrexone (ReVia™), acamprosate, and tiapride. The remaining medication, disulfiram (Antabuse®), may also possess some anticraving activity. Additional medications that have been investigated include ritanserin, which has not been shown to decrease craving or drinking levels in humans, and ondansetron, which shows promise for treating early onset alcoholics, who generally respond poorly to psychosocial treatment alone. Use of anticraving medications in combination (e.g., naltrexone plus acamprosate) may enhance their effectiveness. Future studies should address such issues as optimal dosing regimens and the development of strategies to enhance patient compliance. KEY WORDS: AOD (alcohol and other drug) craving; anti alcohol craving agents; alcohol withdrawal agents; drug therapy; neurobiological theory; alcohol cue; disulfiram; naltrexone; calcium acetylhomotaurinate; dopamine; serotonin uptake inhibitors; buspirone; treatment outcome; reinforcement; neurotransmitters; patient assessment; literature review riteria for defining alcoholism Results of craving research are often tions (i.e., pharmacotherapy) to improve vary widely. Most definitions difficult to interpret,
    [Show full text]
  • Patient Information Leaflet
    Package leaflet : Information for the User anti-arrhythmic medicines, used to treat an uneven heart beat, as these medicines may interact with Zofran & affect the rhythm of the ® heart Zofran Zydis 4mg beta-blocker medicines used to treat certain heart or eye problems, anxiety or prevent migraines, as these medicines may interact with oral lyophilisate Zofran and affect the rhythm of the heart tramadol, a pain killer, as Zofran may reduce the effect of tramadol ondansetron medicines that affect the heart (such as haloperidol or methadone) cancer medicines (especially anthracyclines) as these may interact Read all of this leaflet carefully before you start taking this with Zofran to cause heart arrhythmias medicine because it contains important information for you. medicines used to treat depression and/or anxiety: Keep this leaflet. You may need to read it again. • SSRIs (selective serotonin reuptake inhibitors) including If you have any further questions about your illness or your fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, medicine, ask your doctor, nurse or pharmacist. escitalopram This medicine has been prescribed for you only. Do not pass it on • SNRIs (serotonin noradrenaline reuptake inhibitors) including to others. It may harm them, even if their signs of illness are the venlafaxine, duloxetine same as yours. If you are not sure if any of the above applies to you, talk to your doctor, If you get any side effects, talk to your doctor, nurse or pharmacist. nurse or pharmacist before having Zofran Zydis. This includes any possible side effects not listed in this leaflet. Pregnancy, breast-feeding and fertility What is in this leaflet: 1.
    [Show full text]
  • Safety and Efficacy of a Continuous Infusion, Patient Controlled Anti
    Bone Marrow Transplantation, (1999) 24, 561–566 1999 Stockton Press All rights reserved 0268–3369/99 $15.00 http://www.stockton-press.co.uk/bmt Safety and efficacy of a continuous infusion, patient controlled anti- emetic pump to facilitate outpatient administration of high-dose chemotherapy SP Dix, MK Cord, SJ Howard, JL Coon, RJ Belt and RB Geller Blood and Marrow Transplant Program, Oncology and Hematology Associates and Saint Luke’s Hospital of Kansas City, Kansas City, MO, USA Summary: and colleagues1 described an outpatient BMT care model utilizing intensive clinic support following inpatient admin- We evaluated the combination of diphenhydramine, lor- istration of HDC. This approach facilitated early patient azepam, and dexamethasone delivered as a continuous discharge and significantly decreased the total number of i.v. infusion via an ambulatory infusion pump with days of hospitalization associated with BMT. More patient-activated intermittent dosing (BAD pump) for recently, equipped BMT centers have extended the out- prevention of acute and delayed nausea/vomiting in patient care approach to include administration of HDC in patients receiving high-dose chemotherapy (HDC) for the clinic setting. Success of the total outpatient care peripheral blood progenitor cell (PBPC) mobilization approach is dependent upon the availability of experienced (MOB) or prior to autologous PBPC rescue. The BAD staff and necessary resources as well as implementation of pump was titrated to patient response and tolerance, supportive care strategies designed to minimize morbidity and continued until the patient could tolerate oral anti- in the outpatient setting. emetics. Forty-four patients utilized the BAD pump Despite improvements in supportive care strategies, during 66 chemotherapy courses, 34 (52%) for MOB chemotherapy-induced nausea and vomiting continues to be and 32 (48%) for HDC with autologous PBPC rescue.
    [Show full text]
  • Acute Migraine Treatment
    Acute Migraine Treatment Morris Levin, MD Professor of Neurology Director, Headache Center UCSF Department of Neurology San Francisco, CA Mo Levin Disclosures Consulting Royalties Allergan Oxford University Press Supernus Anadem Press Amgen Castle Connolly Med. Publishing Lilly Wiley Blackwell Mo Levin Disclosures Off label uses of medication DHE Antiemetics Zolmitriptan Learning Objectives At the end of the program attendees will be able to 1. List all important options in the acute treatment of migraine 2. Discuss the evidence and guidelines supporting the major migraine acute treatment options 3. Describe potential adverse effects and medication- medication interactions in acute migraine pharmacological treatment Case 27 y/o woman has suffered ever since she can remember from “sick headaches” . Pain is frontal, increases over time and is generally accompanied by nausea and vomiting. She feels depressed. The headache lasts the rest of the day but after sleeping through the night she awakens asymptomatic 1. Diagnosis 2. Severe Headache relief Diagnosis: What do we need to beware of? • Misdiagnosis of primary headache • Secondary causes of headache Red Flags in HA New (recent onset or change in pattern) Effort or Positional Later onset than usual (middle age or later) Meningismus, Febrile AIDS, Cancer or other known Systemic illness - Neurological or psych symptoms or signs Basic principles of Acute Therapy of Headaches • Diagnose properly, including comorbid conditions • Stratify therapy rather than treat in steps • Treat early
    [Show full text]
  • Hydroxyzine Prescribing Information
    Hydroxyzine Hydroxyzine Hydrochloride Hydrochloride Injection, USP Injection, USP (For Intramuscular Use Only) (For Intramuscular Use Only) Rx Only Rx Only DESCRIPTION: Hydroxyzine hydrochloride has the chemical name of (±)-2-[2-[4-( p-Chloro- a- phenylbenzyl)-1-piperazinyl]ethoxy]ethanol dihydrochloride and occurs as a white, odorless powder which is very soluble in water. It has the following structural formula: Molecular Formula: C 21 H27 ClN 2O2•2HCl Molecular Weight: 447.83 Hydroxyzine Hydrochloride Injection, USP is a sterile aqueous solution intended for intramuscular administration. Each mL contains: Hydroxyzine HCl 25 mg or 50 mg, Benzyl Alcohol 0.9%, and Water for Injection q.s. pH adjusted with Sodium Hydroxide and/or Hydrochloric Acid. CLINICAL PHARMACOLOGY: Hydroxyzine hydrochloride is unrelated chemically to phenothiazine, reserpine, and meprobamate. Hydroxyzine has demonstrated its clinical effectiveness in the chemotherapeutic aspect of the total management of neuroses and emotional disturbances manifested by anxiety, tension, agitation, apprehension or confusion. Hydroxyzine has been shown clinically to be a rapid-acting true ataraxic with a wide margin of safety. It induces a calming effect in anxious, tense, psychoneurotic adults and also in anxious, hyperkinetic children without impairing mental alertness. It is not a cortical depressant, but its action may be due to a suppression of activity in certain key regions of the subcortical area of the central nervous system. Primary skeletal muscle relaxation has been demonstrated experimentally. Hydroxyzine has been shown experimentally to have antispasmodic properties, apparently mediated through interference with the mechanism that responds to spasmogenic agents such as serotonin, acetylcholine, and histamine. Antihistaminic effects have been demonstrated experimentally and confirmed clinically.
    [Show full text]
  • 5-HT3 Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: the Iceberg Still Lies Beneath the Surface
    1521-0081/71/3/383–412$35.00 https://doi.org/10.1124/pr.118.015487 PHARMACOLOGICAL REVIEWS Pharmacol Rev 71:383–412, July 2019 Copyright © 2019 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: JEFFREY M. WITKIN 5-HT3 Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: The Iceberg Still Lies beneath the Surface Gohar Fakhfouri,1 Reza Rahimian,1 Jonas Dyhrfjeld-Johnsen, Mohammad Reza Zirak, and Jean-Martin Beaulieu Department of Psychiatry and Neuroscience, Faculty of Medicine, CERVO Brain Research Centre, Laval University, Quebec, Quebec, Canada (G.F., R.R.); Sensorion SA, Montpellier, France (J.D.-J.); Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran (M.R.Z.); and Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada (J.-M.B.) Abstract. ....................................................................................384 I. Introduction. ..............................................................................384 II. 5-HT3 Receptor Structure, Distribution, and Ligands.........................................384 A. 5-HT3 Receptor Agonists .................................................................385 B. 5-HT3 Receptor Antagonists. ............................................................385 Downloaded from 1. 5-HT3 Receptor Competitive Antagonists..............................................385 2. 5-HT3 Receptor
    [Show full text]
  • Oral Delivery Oct 06 18/1/07 20:19 Page 1
    Oral Delivery Oct 06 18/1/07 20:19 Page 1 ORAL DRUG DELIVERY WHEN YOU FIND THE HOLY GRAIL www.ondrugdelivery.com Oral Delivery Oct 06 18/1/07 20:19 Page 2 “Oral drug delivery: when you find the Holy Grail” CONTENTS This edition is one in a series of sponsored themed publications from ONdrugDelivery Ltd. Each issue focuses on a specific topic within the field of drug delivery, and contain up to eight articles contributed Introductory comment by leaders in that field. Guy Furness 3 Full contact information appears alongside each article. Contributing companies would be delighted to hear Growing sales and new opportunities for oral from interested readers directly. ONdrugDelivery fast dissolve would also be very pleased to pass on to authors, or Dr Ian Muir answer as appropriate, any queries you might have in relation to this publication or others in the series. Cardinal Health 4-6 During 2007 ONdrugDelivery will be covering the following topics: From oral drug delivery technology to proprietary February: Transdermal delivery product development April: Pulmonary delivery Dr Anand Baichwal, Thomas Sciascia, MD June: Prefilled syringes Penwest Pharmaceuticals 7-10 August: Oral drug delivery October: Delivering injectables December: Nanotechnology in drug delivery Combination oral products: the time is now! Fred H. Miller To start a FREE subscription (pdf or print) to INNERCAP Technologies 12-15 ONdrugDelivery’s sponsored series, please contact ONdrugDelivery directly (details below) Combining technologies without compromise: taste masking + ODT + modified release Steve Ellul Eurand 16-19 Oral drug delivery: the Holy Grail To find out more about how your company can Ms Bavani Shankar participate in 2007, please contact ONdrugDelivery Emisphere Technologies 20-21 directly (details below).
    [Show full text]
  • Effect of Naltrexone and Ondansetron on Alcohol Cue–Induced Activation of the Ventral Striatum in Alcohol-Dependent People
    ORIGINAL ARTICLE Effect of Naltrexone and Ondansetron on Alcohol Cue–Induced Activation of the Ventral Striatum in Alcohol-Dependent People Hugh Myrick, MD; Raymond F. Anton, MD; Xingbao Li, MD; Scott Henderson, BA; Patrick K. Randall, PhD; Konstantin Voronin, MD, PhD Context: Medication for the treatment of alcoholism is double-blind randomly assigned daily dosing with 50 mg currently not particularly robust. Neuroimaging tech- of naltrexone (n=23), 0.50 mg of ondansetron hydro- niques might predict which medications could be use- chloride (n=23), the combination of the 2 medications ful in the treatment of alcohol dependence. (n=20), or matching placebos (n=24). Objective: To explore the effect of naltrexone, ondanse- Main Outcome Measures: Difference in brain blood tron hydrochloride, or the combination of these medi- oxygen level–dependent magnetic resonance when view- cations on cue-induced craving and ventral striatum ac- ing alcohol pictures vs neutral beverage pictures with a tivation. particular focus on ventral striatum activity comparison across medication groups. Self-ratings of alcohol craving. Design: Functional brain imaging was conducted dur- ing alcohol cue presentation. Results: The combination treatment decreased craving for alcohol. Naltrexone with (P=.02) or without (P=.049) Setting: Participants were recruited from the general ondansetron decreased alcohol cue–induced activation community following media advertisement. Experimen- of the ventral striatum. Ondansetron by itself was simi- tal procedures were performed in the magnetic reso- lar to naltrexone and the combination in the overall analy- nance imaging suite of a major training hospital and medi- sis but intermediate in a region-specific analysis. cal research institute.
    [Show full text]
  • Alternative Forms of Oral Drug Delivery for Pediatric Patients Marcia L
    PEDIATRIC PHARMACOTHERAPY A Monthly Newsletter for Health Care Professionals from the University of Virginia Children’s Hospital Volume 19 Number 3 March 2013 Alternative Forms of Oral Drug Delivery for Pediatric Patients Marcia L. Buck, Pharm.D., FCCP, FPPAG he lack of an appropriate dosage form the concentration versus time curve (AUC) of T limits the use of many medications that 45% for lopinavir and 47% for ritonavir (p = may potentially benefit children. While this has 0.003 and 0.006, respectively). been a long-standing problem for pediatric healthcare providers, little attention has been Cutting tablets, another common practice, may paid to remedying it until recently. In 2005 the be acceptable for some drugs, however this Eunice Kennedy Shriver National Institute for practice can introduce considerable variability Child Health and Human Development, joined between doses. In drugs with a narrow by representatives from the Food and Drug therapeutic index, such as levothyroxine, this Administration (FDA), academic medicine, and variability may be enough to produce clinically the pharmaceutical industry, formed the United significant changes in clinical response.7 When States (US) Pediatric Formulations Initiative in cutting a tablet is necessary, family members an effort to stimulate research in pediatric should receive specific instructions on the formulation technology.1 Similar work by the process, including the proper use of a tablet European Medication Agency (EMA) led to the splitter. Family members involved in dose development of the European Pediatric preparation should also understand how to Formulation Initiative.2 In addition, the World dispose of unused drug and the need to avoid Health Organization launched a global initiative repeated exposure to drugs that have in 2007 entitled “Make Medicines Child Size” to carcinogenic or teratogenic properties.
    [Show full text]
  • Olanzapine (Zyprexa, Zydis) ALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES
    Olanzapine (Zyprexa, Zydis) ALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES Client’s Name ______________________________________________________ Date _____________________ Initial Medication Instructions __________________________________________________________________ What does this medication help to treat? Schizophrenia, schizoaffective disorder, bipolar disorder or other conditions. Symptoms of these conditions are: Poor concentration Hallucinations (hearing voices) Rapid thoughts Delusions (beliefs that are false) Pacing and restlessness Fearful feelings Fluctuations in mood Paranoia or suspiciousness Insomnia Agitation, aggression, or hostility Olanzapine is sometimes prescribed for other uses; ask your Lack of energy or motivation health care professional for more information Other information . This medication can take up to 6 weeks to achieve desired results, but you should begin to see improvement within the first two weeks of treatment. It is very important to keep all appointments with your clinic, prescriber, or laboratory. Side Effects and Management Common (greater than 10 in 100 clients on this medication) Drowsiness Use caution when driving or operating machinery. Ask you prescriber about taking your dose at bedtime if drowsiness occurs. Weight Gain and Avoid foods high in fat and sugar. Eat balanced meals and maintain an active lifestyle. Individuals Increased appetite may gain 10-15 pounds over 1-2 months. Dizziness Arise slowly from chairs. Dangle feet off the side of the bed before getting up. Headache You may take aspirin or Tylenol to relieve your headache. The headache side effect of this medication should subside over time. Talk to your prescriber if headaches are severe or persist for more than one day. Restlessness, Agitation Talk to your prescriber about possibly adjusting the dose of your olanzapine.
    [Show full text]
  • Hallucinogens: an Update
    National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Hallucinogens: An Update 146 U.S. Department of Health and Human Services • Public Health Service • National Institutes of Health Hallucinogens: An Update Editors: Geraline C. Lin, Ph.D. National Institute on Drug Abuse Richard A. Glennon, Ph.D. Virginia Commonwealth University NIDA Research Monograph 146 1994 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 ACKNOWLEDGEMENT This monograph is based on the papers from a technical review on “Hallucinogens: An Update” held on July 13-14, 1992. The review meeting was sponsored by the National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services. The U.S. Government does not endorse or favor any specific commercial product or company.
    [Show full text]